Compare UTF & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTF | SRPT |
|---|---|---|
| Founded | N/A | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.5B |
| IPO Year | 2004 | 2000 |
| Metric | UTF | SRPT |
|---|---|---|
| Price | $27.68 | $18.89 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 29 |
| Target Price | N/A | ★ $25.85 |
| AVG Volume (30 Days) | 285.7K | ★ 3.6M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | ★ $2,198,237,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.13 |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $23.42 | $10.42 |
| 52 Week High | $27.90 | $25.32 |
| Indicator | UTF | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 59.61 | 56.25 |
| Support Level | $26.54 | $15.55 |
| Resistance Level | $27.90 | $19.70 |
| Average True Range (ATR) | 0.31 | 1.05 |
| MACD | 0.01 | 0.37 |
| Stochastic Oscillator | 81.00 | 62.87 |
Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. Under normal market conditions, the fund invests the majority of its managed assets in securities issued by infrastructure companies, which consist of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.